Kirin to Release “Slow Drink(R)” Advertisements Promoting Responsible Drinking in Pursuit of Zero Harmful Drinking During the Holiday Season
10.12.2019 12:30:00 EET | Business Wire | Press release
Kirin Holdings Company, Limited (TOKYO:2503) (President and CEO: Yoshinori Isozaki) plans to begin running advertisements promoting responsible drinking on Twitter (Japanese version) starting Friday, December 6, ahead of the peak season for New Year gatherings. The aim of the ads is to prevent the binge drinking, speed drinking, and other dangerous modes of consuming alcohol often observed at these events, and to promote and encourage responsible drinking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005439/en/
IMAGE(1) (Graphic: Business Wire)
The Company unveiled the Kirin Group CSV1 Purpose, which provides guidelines for creating shared value with society and promoting sustainable growth, and serves as long-term, non-financial targets incorporated into the Kirin Group Vision 2027, which represents the Group’s long-term management vision.
The ad campaign is part of our efforts to play a leading role as a responsible alcohol producer as called for in the CSV Purpose.
1CSV: Creating Shared Value. The premise is about creating value that can be shared with customers and society.
The number of people transported emergently to hospitals for acute alcohol poisoning is increasing each year;2 roughly half of those people are in their 20s. The advertisements emphasize the life-threatening danger of binge drinking and other harmful modes of consuming alcohol, and promote responsible drinking namely to people in their 20s who have little experience with alcohol. The ads also communicate the importance of responsible drinking to fulfill the Company’s social responsibility as a manufacturer and seller of alcoholic beverages.
2According to investigations by the fire departments of Tokyo, Osaka, and Nagoya
The Company also plans to stream subtitled English versions of the advertisements with the aim of sharing the message with the world to address the global social issue of harmful alcohol consumption.
YouTube release of subtitled English version: Link: https://youtu.be/0ORj-ZxJdGs
Title: SLOW DRINK (I was just going a little too fast) English version
The Company is proposing “Slow Drink(R)” as a new method of drinking in which people take a relaxed approach to consuming alcohol: being smart and keeping the situation pleasant by drinking in moderation while enjoying good food and conversation with others.
We have created an official logo for “Slow Drink(R)”, and intend to promote new values for alcohol as part of the public education campaign for responsible drinking we are undertaking as an alcohol producer.
In the business environment in which the Kirin Group operates, companies are under increasing pressure to tackle social issues, which include health problems caused by harmful drinking.
We are committed to promoting zero harmful drinking and ensuring that people will continue to enjoy a responsible drinking culture for generations to come.
The Kirin Group is committed to its role as a responsible alcohol producer and addressing the three key social issues: “health and well-being,” “community engagement,” and “the environment.” By fulfilling these commitments, the Group can bring joy to society and a brighter future to our customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005439/en/
Contact information
For press inquiries, contact:
Corporate Communications Department, Kirin Holdings Co., Ltd.
Tel +81-3-6837-7028
For consumer inquiries, call:
Customer Service, Kirin Holdings Co., Ltd. at 0120-770-502 (toll-free if called from within Japan)
Email address: izawa@ccpr.jp (Ryo Izawa)
Kirin Website: https://www.kirin.co.jp (Images available for download)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
